acut
phase
respons
apr
one
main
reaction
innat
host
defenc
system
baumann
gauldi
paltrinieri
refer
complex
phenomenon
occur
earli
stage
inflamm
preced
develop
acquir
immun
respons
baumann
gauldi
ceron
et
al
apr
consequ
product
releas
sever
cytokin
interleukin
il
tumour
necrosi
factor
tnf
relev
et
al
paltrinieri
mediat
induc
variou
chang
bodi
includ
fever
leucocytosi
modul
protein
synthesi
hepatocyt
baumann
gauldi
ceciliani
et
al
posit
acut
phase
protein
app
increas
inflamm
believ
act
immunomodul
differ
way
reinforc
bodi
innat
defenc
inflamm
petersen
et
al
eckersal
bell
relev
well
describ
posit
app
cat
agp
serum
saa
petersen
et
al
ceron
et
al
paltrinieri
eckersal
bell
agp
believ
act
immunomodul
protein
neutrophil
respons
secondari
inflamm
stimul
product
antagonist
macrophag
reduc
platelet
aggreg
lymphoid
prolifer
modul
product
cytokin
circul
lymphocyt
hochepi
et
al
increas
differ
cat
infecti
diseas
describ
duthi
et
al
paltrinieri
et
al
paltrinieri
et
al
retrovir
infect
cat
previou
studi
report
increas
duthi
et
al
recent
one
found
fiv
posit
cat
lower
concentr
agp
healthi
one
korman
et
al
saa
small
protein
appear
precursor
amyloid
protein
major
protein
potenti
involv
varieti
chronic
inflammatori
diseas
uhlar
whitehead
among
major
function
saa
act
scaveng
oxidis
metabolit
protect
tissu
excess
damag
induc
inflamm
et
al
agp
measur
report
differ
felin
diseas
kajikawa
et
al
sasaki
et
al
giordano
et
al
tamamoto
et
al
protein
crp
first
app
describ
consid
major
protein
differ
speci
human
dog
ceron
et
al
schultz
arnold
among
major
function
immun
system
crp
involv
activ
classic
complement
pathway
enhanc
phagocytosi
even
modul
polymorphonuclear
cell
schultz
arnold
crp
appear
involv
felin
acut
phase
reaction
well
studi
document
cat
ceron
et
al
human
medicin
sever
studi
describ
increas
human
immunodefici
viru
hiv
posit
patient
jahoor
et
al
treiting
et
al
even
immunomodul
therapi
exogen
barbai
et
al
despit
similar
hiv
fiv
hosi
et
al
hartmann
crp
behaviour
fiv
posit
cat
undergo
immunomodul
therapi
remain
unknown
recombin
felin
therapi
virbagen
virbac
immunomodul
drug
play
import
role
therapeut
approach
variou
felin
diseas
includ
cat
retroviru
infect
collado
et
al
studi
describ
clinic
improv
retrovir
infect
cat
therapi
de
mari
et
al
domenech
et
al
gil
et
al
littl
known
immunolog
base
support
find
report
clinic
improv
increas
surviv
time
reduct
concurr
viral
excret
appear
involv
innat
respons
de
mari
et
al
domenech
et
al
gil
et
al
studi
describ
use
app
clinic
monitor
tool
immun
system
anim
undergo
scarc
therefor
main
object
studi
determin
whether
therapi
influenc
app
name
saa
agp
crp
natur
retrovir
infect
cat
whether
paramet
may
good
predictor
stimul
sixteen
natur
retrovir
infect
cat
live
anim
shelter
lisbon
select
studi
cat
accustom
shelter
environ
live
least
week
start
protocol
accord
previou
studi
de
mari
et
al
gil
et
al
inclus
criteria
includ
follow
cat
age
breed
sex
heterogen
popul
cat
show
least
one
clinic
sign
potenti
relat
retrovir
infect
cat
previous
shown
posit
rapid
fiv
andor
felv
test
result
exclus
criteria
cat
type
malignancyneoplasia
lymphoma
lymphoid
leukaemia
cat
receiv
immunomodul
drug
corticosteroid
week
studi
cat
receiv
antibiot
drug
week
studi
cat
complet
therapeut
protocol
initi
cat
retest
confirm
fivfelv
infect
use
commerci
avail
immunoabsorb
assay
elisa
virachekfiv
virachekfelv
synbiot
anim
hous
two
differ
catteri
accord
fiv
felv
statu
anim
concurr
infect
fiv
felv
hous
felv
catteri
cat
catteri
treat
studi
incom
anim
allow
purpos
analysi
cat
divid
three
differ
group
accord
retrovir
statu
fiv
posit
cat
felv
posit
cat
anim
cat
live
good
condit
agreement
current
ethic
european
welfar
standard
procedur
involv
manipul
anim
consent
approv
local
committe
ethic
anim
welfar
veterinari
medicinetechn
univers
lisbon
also
clinic
director
anim
shelter
basi
assumpt
deriv
two
previous
publish
doubl
arm
trial
de
mari
et
al
domenech
et
al
studi
perform
studi
model
time
point
therapi
consid
anim
control
studi
assess
therapi
design
consid
repres
stage
anim
treatment
anim
treat
accord
licens
protocol
three
cycl
inject
day
treatment
cycl
consist
five
subcutan
sc
inject
day
day
vial
omega
virbac
reconstitut
accompani
salin
diluent
accord
manufactur
recommend
immedi
treatment
treatment
administ
two
veterinari
clinician
research
team
project
studi
conduct
despit
exclus
criteria
appli
anim
need
support
treatment
therapi
consequ
potenti
amoxycillin
hepat
protect
ursodeoxychol
acid
sylimarin
andor
fluid
therapi
allow
although
antibiot
may
direct
immunomodul
effect
potenti
amoxycillin
allow
take
account
empir
use
frequent
administr
retroviru
infect
cat
suspect
bacteri
infect
antibiot
potenti
amoxycillin
corticosteroid
drug
permit
avoid
possibl
immunomodul
effect
blood
sampl
collect
venipunctur
jugular
vein
four
specif
time
point
name
therapi
allow
better
evalu
simpler
blood
sampl
collect
cat
subject
mild
sedat
mgkg
butorphanol
solut
sc
dolorex
intervet
portug
serum
sampl
collect
clot
sampl
occur
centrifug
minut
subsequ
frozen
analys
saa
crp
measur
specif
elisa
kit
phase
saa
multispeciestridelta
cat
crp
elisakamiya
biomed
compani
respect
agp
determin
singl
radial
immunodiffus
felin
agp
srid
tridelta
measur
perform
accord
manufactur
instruct
statist
evalu
perform
use
r
statist
softwar
small
sampl
size
nonparametr
statist
test
use
test
appli
assess
differ
among
group
time
point
differ
observ
pairwis
comparison
appli
assess
group
variat
time
friedman
rank
sum
test
use
nonparametr
test
appli
took
account
magnitud
also
predomin
sign
posit
neg
effect
signific
set
p
cat
complet
licens
therapeut
protocol
statist
differ
group
observ
apart
crp
agp
saa
group
similar
time
point
cat
behav
similarli
therefor
analysi
time
group
consid
togeth
global
result
present
fig
signific
increas
saa
concentr
observ
increas
saa
anim
decreas
saa
mean
saa
concentr
time
higher
valu
remain
upper
limit
refer
interv
ri
agp
three
group
also
similar
time
point
apart
felv
cat
show
higher
mean
valu
fiv
cat
fiv
versu
fiv
versu
felv
felv
versu
fig
signific
overal
increas
time
agp
concentr
agp
increas
cat
decreas
basal
valu
within
ri
therapi
mean
valu
felv
cat
exceed
upper
limit
ri
fiv
result
remain
within
ri
crp
three
group
statist
indistinguish
studi
apart
statist
signific
differ
time
point
felv
cat
higher
crp
concentr
fiv
cat
fiv
versu
fiv
versu
felv
felv
versu
result
crp
valu
present
fig
increas
crp
concentr
cat
increas
crp
cat
increas
approxim
time
baselin
valu
valu
upper
limit
ri
fiv
felv
cat
one
cat
felv
group
cat
receiv
support
therapi
name
intraven
fluid
suspect
otitisvestibular
syndrom
fact
consid
factor
includ
consid
clinic
score
anim
also
receiv
potenti
amoxycilin
end
studi
app
profil
cat
similar
wider
group
data
relat
clinic
sign
concurr
viral
load
name
caliciviru
herpesviru
coronaviru
parvoviru
cat
time
period
previous
report
gil
et
al
herpesviru
coronaviru
viral
load
assess
polymeras
chain
reaction
pcr
caliciviru
parvoviru
statu
determin
gil
et
al
result
summaris
tabl
also
includ
detail
app
result
clinic
sign
improv
concurr
viral
excret
decreas
major
cat
two
cat
increas
coronoviru
excret
remain
asymptomat
cat
posit
caliciviru
singl
cat
excret
parvoviru
becam
neg
end
studi
mean
overal
signific
decreas
concurr
viral
infect
simultan
major
cat
increas
app
concentr
studi
describ
chang
observ
serum
concentr
three
differ
app
cat
natur
infect
retrovirus
undergo
therapi
studi
consid
perform
like
reliabl
approach
studi
natur
infect
time
infect
viru
uncertain
studi
use
accord
licens
protocol
approv
veterinari
use
felin
retroviru
infect
although
studi
publish
clinic
improv
cat
undergo
therapi
well
document
doubl
arm
trial
de
mari
et
al
domenech
et
al
studi
provid
inform
regard
paramet
complementari
main
clinic
sign
concurr
viral
excret
data
previous
publish
gil
et
al
clarifi
pathophysiolog
phenomena
behind
immun
stimul
sever
author
suggest
ceron
et
al
concentr
app
may
within
ri
even
anim
diseas
measur
paramet
monitor
inflamm
stimulu
without
difficulti
use
individu
anim
refer
consid
practic
reason
approach
bypass
problem
ceron
et
al
therefor
previou
human
studi
evalu
app
wasunna
et
al
barbai
et
al
anim
act
control
time
point
therapi
consid
baselin
valu
cat
subsequ
possibl
studi
individu
trend
therapi
although
consensu
upper
lower
limit
valu
measur
app
suggest
rang
kit
use
particularli
agp
crp
cat
higher
mean
valu
upper
limit
time
point
howev
previou
studi
describ
higher
valu
healthi
cat
kajikawa
et
al
selt
et
al
adapt
would
expand
recommend
ri
comparison
individu
valu
therapi
particular
relev
differ
consid
relev
studi
whether
ri
concentr
saa
agp
three
group
studi
fiv
felv
anim
behav
similarli
demonstr
increas
valu
therapi
group
statist
differ
except
agp
particular
variat
secondari
fact
fiv
group
demonstr
lower
agp
valu
compar
felv
cat
despit
low
number
anim
possibl
explan
may
diseas
lead
particular
alter
time
point
howev
consid
statist
differ
evid
particular
time
point
find
consid
biolog
signific
accord
previou
studi
report
agp
saa
good
predictor
immunomodul
kajikawa
et
al
hochepi
et
al
result
support
hypothesi
therapi
may
modul
innat
mechan
app
may
use
monitor
tool
demonstr
modul
respons
crp
except
three
group
cat
also
similar
throughout
studi
particular
variat
due
fact
felv
cat
higher
valu
fiv
cat
agp
may
due
variou
caus
uncontrol
infect
shelter
even
natur
progress
retrovir
diseas
begin
end
treatment
signific
increas
crp
concentr
note
although
crp
consid
use
biomark
inflamm
cat
studi
show
app
behav
similarli
saa
agp
therefor
contrast
previou
studi
crp
may
also
valu
biomark
felin
inflamm
increas
similar
magnitud
app
measur
recent
studi
describ
evolut
differ
app
name
saa
agp
fiv
cat
follow
mycoplasma
haemof
candidatu
mycoplasma
infect
korman
et
al
studi
reveal
fiv
infect
significantli
affect
apr
mycoplasma
despit
remain
within
ri
fiv
posit
cat
demonstr
lower
concentr
agp
cat
contrast
previou
studi
suggest
agp
increas
fiv
cat
duthi
et
al
take
account
seem
reason
consid
fiv
cat
abl
develop
effici
acut
phase
may
lead
rise
app
regard
convent
assess
immun
system
retrovir
infect
cat
previou
studi
conclud
hyperglobulinaemia
commonli
observ
fiv
cat
may
due
hyperactiv
evid
diseas
progress
gleich
hartmann
contrast
due
progress
defect
helper
felv
cat
usual
present
hyperglobulinaemia
prone
sever
cytopenia
gleich
hartmann
accord
studi
increas
app
similar
fiv
felv
suggest
stimul
must
basi
two
group
studi
perform
correl
app
retrovir
infect
cat
whether
interfer
serum
protein
electrophoresi
profil
remain
unclear
previous
demonstr
result
overal
clinic
improv
fiv
also
felv
cat
gil
et
al
clinic
sign
evalu
decreas
three
group
fiv
felv
mean
overal
improv
symptomat
cat
total
improv
clinic
sign
remain
stabl
furthermor
signific
decreas
excret
virus
also
observ
concomitantli
gil
et
al
correl
app
profil
previou
result
observ
app
concentr
increas
cat
concurr
improv
clinic
sign
reduc
viral
excret
find
consist
even
cat
low
clinic
score
score
remain
stabl
therapi
recognis
app
may
increas
differ
situat
chronic
infect
sever
inflamm
ceron
et
al
paltrinieri
concurr
clinic
improv
decreas
load
virus
reinforc
sustain
hypothesi
therapi
potenti
immun
respons
may
involv
benefici
app
increas
treat
anim
conclus
measur
app
significantli
increas
reveal
potenti
respons
natur
infect
cat
therapi
human
describ
administr
hiv
patient
induc
increas
crp
posit
correl
increas
cell
count
barbai
et
al
find
report
possibl
involv
crp
immun
stimul
barbai
et
al
convers
previous
describ
ratio
chang
cat
domenech
et
al
therefor
true
mechan
induc
increas
app
remain
unclear
characteris
immun
respons
therapi
studi
requir
correl
find
paramet
cytokin
profil
result
studi
suggest
app
may
promis
predictor
stimul
natur
retrovir
infect
cat
undergo
therapi
futur
could
combin
togeth
may
help
individu
monitor
assess
therapi
